@morgans rate Impedimed (IPD, Outperform, Price Target A$0.30)
@morgans rate Impedimed (IPD, Outperform, Price Target A$0.30). Impedimed announces a service agreement with the Institut Curie for the first prospective, multi-centre, clinical trial utilising L-Dex® in France. Institut Curie is one of Europe's leading oncology research centres, with state-of-the-art hospitals and a reputation for accelerating the advancement of new clinical tools for the medical community. This five-year, randomised controlled trial will take place at five centres in France to study early detection and treatment of lymphoedema related to breast cancer. The study is designed to follow 800 women for two years with L-Dex as the primary measurement criteria. Patients will be measured before cancer treatment, and every four to six months, up to twenty-four months post-treatment. Our comment - this is in line with Management plans and our expectations.
The Livewire Equities feed brings you a range of insights that relate to Australian equities
No areas of expertise